Invega Formulations and Indications
Invega (paliperidone) is available in four distinct formulations: oral extended-release tablets and three long-acting injectable suspensions with different dosing intervals (monthly, 3-monthly, and 6-monthly), all FDA-approved for schizophrenia treatment, with the oral formulation also indicated for schizoaffective disorder. 1
Available Formulations
Oral Extended-Release Tablets (Invega®)
- Strengths: 1.5 mg (orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) 1
- Technology: OROS® osmotic drug-release system that delivers paliperidone at a controlled rate over 24 hours, allowing once-daily dosing without titration 1
- Mechanism: Uses osmotic pressure with a trilayer core and semipermeable membrane; the tablet shell passes through the GI tract intact and is eliminated in stool 1
Long-Acting Injectable Suspensions
- Once-monthly (PP1M): Paliperidone palmitate intramuscular suspension, approved since 2009 2
- 3-monthly (PP3M/Invega Trinza®): Approved for maintenance treatment in patients adequately treated with PP1M 3
- 6-monthly (PP6M/Invega Hafyera®): The newest formulation approved for schizophrenia treatment, requiring prior stabilization on shorter-acting formulations 4
FDA-Approved Indications
Oral Extended-Release Tablets 1
Schizophrenia:
- Acute treatment
- Maintenance treatment
Schizoaffective Disorder:
- Acute treatment as monotherapy
- Acute treatment as adjunct to mood stabilizers and/or antidepressants
Long-Acting Injectable Formulations
- Primary indication: Schizophrenia maintenance treatment 4, 3
- PP1M: Also approved for schizoaffective disorder 2
- PP3M and PP6M: Require prior stabilization on shorter-acting paliperidone formulations before initiation
Clinical Context from Guidelines
The 2025 INTEGRATE guidelines position paliperidone (along with risperidone, amisulpride, and olanzapine) as a second-line option for patients whose first antipsychotic was a D2 partial agonist and who experienced inadequate response after 4 weeks at therapeutic doses 5. This reflects paliperidone's pharmacodynamic profile as a D2 and 5HT2A antagonist with a different mechanism than partial agonists.
Long-acting injectable formulations remain underutilized despite their benefits in improving adherence and reducing relapse rates 6. The availability of multiple dosing intervals (monthly, 3-monthly, 6-monthly) provides flexibility for patients who may have difficulty accessing healthcare or prefer less frequent injections 4.
Key Clinical Considerations
Pharmacokinetics: Paliperidone has a terminal elimination half-life of approximately 23 hours for oral formulations, with peak concentrations reached 24 hours post-dose 1. The extended-release technology minimizes peak-trough fluctuations, providing stable plasma concentrations.
Metabolic advantage: Unlike risperidone (its parent compound), paliperidone undergoes predominantly renal excretion with negligible hepatic biotransformation, resulting in low risk for metabolic drug-drug interactions 7, 8.
Tolerability profile: Dose-dependent extrapyramidal symptoms occur in approximately 25% of patients at higher doses (9-12 mg/day), with prolactin elevation being a consistent concern across all formulations 9, 8. However, paliperidone ER demonstrates low liability for metabolic effects (weight gain, hyperglycemia, lipid dysregulation) and cardiovascular adverse effects 7.